SCHEMBL16670160

SCHEMBL16670160

O=C(O)N1CCC(Oc2ccc3cc(-c4nc5ccccc5o4)c(=O)oc3c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 10/20 0.52
▸ NPC1 O15118 9/20 0.52
▸ RAB9A P51151 9/20 0.52
▸ ALDH1A1 P00352 7/20 0.52
▸ HPGD P15428 7/20 0.52
▸ SMN1; SMN2 Q16637 7/20 0.52
▸ MAPT P10636 6/20 0.52
▸ GLA P06280 4/20 0.52
▸ GAA P10253 4/20 0.52
▸ CASP1 P29466 2/20 0.52
▸ CASP7 P55210 2/20 0.52
▸ HSD17B10 Q99714 2/20 0.52
▸ TP53 P04637 2/20 0.52
▸ PKM P14618 1/20 0.52
▸ MAOB P27338 4/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ ACSL1 P33121 1/20 0.46
▸ PRKCZ Q05513 1/20 0.46
▸ KMT2A Q03164 5/20 0.44
▸ MEN1 O00255 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15086544 0.88 GPR119 (0.51) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL16674817 0.85 KDM4E (0.59) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL15069376 0.84 PRKCZ (0.60) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL381288 0.76 KDM4E (0.67) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL9149718 0.74 KDM4E (0.63) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL7898144 0.73 KDM4E (0.62) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL22372349 0.73 KDM4E (0.58) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL25186260 0.72 HRH3 (0.49) NPC1RAB9AHPGD
SCHEMBL2490607 0.72 KDM4E (0.74) KDM4ENPC1RAB9AALDH1A1HPGD
SCHEMBL9723318 0.72 MAPT (0.74) KDM4ENPC1RAB9AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 — — US disclosed
EP-2797592-B1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2019-08-28 — — EP disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 — — US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM17, RBM22 KDM4E 829/4885NPC1 4329/4885RAB9A 3292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback